SecBot SecBot
SECBOTREPLAY Home › Report › CABA

CABA · Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus…

Cabaletta Bio · PRESS-RELEASE filed May 14, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 14, 2026 at 07:05 ET

Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal and typical for a pre-commercial biotech. The key positive is the $150M oversubscribed financing closed in May 2026, extending the cash runway into mid-2027, and encouraging PC-free clinical data from the RESET-PV study presented at ASGCT. The stock is likely to trade on pipeline catalysts (EULAR data in June, lupus data in 2H26) rather than the minor EPS miss.

  • Q1 2026 EPS of -$0.40 vs consensus -$0.39 (3.1% miss)
  • No revenue reported (pre-commercial stage)
  • Cash, cash equivalents and short-term investments of $116.6M as of March 31, 2026
  • Closed $150M registered direct offering in May 2026, extending cash runway into mid-2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access